Mycobacterium tuberculosis evolutionary pathogenesis and its putative impact on drug development. (August 2014)

• Record Type: Journal Article
• Authors: Chevalier, Fabien Le; Cascioferro, Alessandro; Majlessi, Laleh; Herrmann, Jean Louis; Brosch, Roland
• Is Part Of: Future microbiology. Volume 9:Number 8(2014:Aug.)
• Page Start: 969
• Page End: 985
• Publication Date: 2014-08
• Subjects: attenuation -- drug development -- evolution -- Mycobacterium tuberculosis -- secretion systems -- virulence factors; Microbiology -- Research -- Periodicals; 616.9041
• DOI: 10.2217/fmb.14.70
• Languages: English
• ISSNs: 1746-0913

Abstract

ABSTRACT : Mycobacterium tuberculosis, the etiological agent of human TB, is the most important mycobacterial pathogen in terms of global patient numbers and gravity of disease. The molecular mechanisms by which M. tuberculosis causes disease are complex and the result of host–pathogen coevolution that might have started already in the time of its Mycobacterium canettii -like progenitors. Despite research progress, M. tuberculosis still holds many secrets of its successful strategy for circumventing host defences, persisting in the host and developing resistance, which makes anti-TB treatment regimens extremely long and often inefficient. Here, we discuss what we have learned from recent studies on the evolution of the pathogen and its putative new drug targets that are essential for mycobacterial growth under in vitro or in vivo conditions.